VRTX analyst estimates
Vertex (VRTX) analyst ratings, the average price target and its range, and every firm's latest call.
- 24 firms rate VRTX: 21 buy, 2 hold, 1 sell.
- The average price target is $579.29 from None analysts, from $350.00 to $665.00.
VRTX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Nov 3, 2026 | TD Cowen | Vertex (VRTX) PT Raised to $575 at TD Cowen | $575.00 |
| Nov 3, 2026 | Wells Fargo | Vertex (VRTX) PT Raised to $650 at Wells Fargo | $650.00 |
| Nov 3, 2026 | J.P. Morgan | Vertex (VRTX) PT Raised to $570 at JPMorgan | $570.00 |
| Nov 3, 2026 | Cantor Fitzgerald | Vertex (VRTX) PT Raised to $619 at Cantor Fitzgerald | $619.00 |
| Oct 8, 2026 | RBC Capital | Vertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital | $576.00 |
| Sep 28, 2026 | UBS | Vertex Pharmaceuticals price target raised to $615 from $585 at UBS | $615.00 |
| Sep 23, 2026 | Jefferies | Vertex (VRTX) PT Raised to $640 at Jefferies | $640.00 |
| Sep 22, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX) | $641.00 |
| Sep 1, 2026 | Goldman Sachs | Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs | $653.00 |
| Sep 1, 2026 | Morgan Stanley | Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley | $665.00 |
| Aug 11, 2026 | Bernstein | Bernstein SocGen Reiterates Outperform Rating on Vertex (VRTX) | $608.00 |
| Aug 10, 2026 | Wolfe Research | Vertex (VRTX) PT Raised to $562 at Wolfe Research | $562.00 |
| Aug 5, 2026 | Barclays | Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays | $617.00 |
| Aug 5, 2026 | Truist Financial | Vertex Pharmaceuticals price target raised to $565 from $560 at Truist | $565.00 |
| Aug 4, 2026 | Cantor Fitzgerald | Vertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald | $595.00 |